{
    "clinical_study": {
        "@rank": "72402", 
        "brief_summary": {
            "textblock": "To optimize Mycobacterium avium Complex (MAC) prophylaxis in AIDS patients by measuring\n      serum rifabutin levels and adjusting the dose accordingly. To combine rifabutin with\n      ethambutol to examine the effect of combination therapy in preventing or delaying the\n      incidence of MAC bacteremia in this patient population."
        }, 
        "brief_title": "A Study of Rifabutin, Used Alone or With Ethambutol in the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in Patients With AIDS", 
        "condition": [
            "Mycobacterium Avium-Intracellulare Infection", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Bacteremia", 
                "Mycobacterium Infections", 
                "Mycobacterium avium-intracellulare Infection"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients are randomized to receive oral rifabutin alone or rifabutin/ethambutol daily for 12\n      months, with possible continuation of medicine lifelong. Doses will be adjusted to maintain\n      minimum blood levels of the drugs."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Required:\n\n          -  AZT, d4T, ddI, or ddC.\n\n          -  Antipneumocystis prophylaxis.\n\n        Allowed:\n\n          -  Short course (< 14 days) of ciprofloxacin for acute infections.\n\n        Patients must have:\n\n          -  AIDS.\n\n          -  CD4 count <= 100 cells/mm3.\n\n          -  NO prior or current MAC infection.\n\n        Prior Medication:\n\n        Required:\n\n          -  Antipneumocystis prophylaxis for at least 4 weeks prior to study entry.\n\n        Allowed:\n\n          -  Prior rifabutin.\n\n          -  Prior ethambutol.\n\n          -  Prior clarithromycin.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Positive tuberculin skin test (PPD > 5 mm).\n\n          -  Active M. tuberculosis.\n\n          -  Perceived as unreliable or unavailable for frequent monitoring.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Other antiretrovirals not specifically allowed.\n\n          -  All investigational drugs.\n\n          -  Other antimycobacterial therapy, such as clarithromycin, azithromycin, rifampin,\n             clofazimine, amikacin, streptomycin, isoniazid, cycloserine, ethionamide, and\n             ciprofloxacin (>= 14 days).\n\n        Patients with the following prior conditions are excluded:\n\n        Known hypersensitivity to rifabutin, rifampin, or other rifamycins and/or ethambutol.\n\n        Prior Medication:\n\n        Excluded within 4 weeks prior to study entry:\n\n          -  Rifampin.\n\n          -  Isoniazid.\n\n          -  Clofazimine.\n\n          -  Cycloserine.\n\n          -  Ethionamide.\n\n          -  Amikacin.\n\n          -  Ciprofloxacin."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "200", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002343", 
            "org_study_id": "048E", 
            "secondary_id": "CS 087287-000"
        }, 
        "intervention": [
            {
                "intervention_name": "Ethambutol hydrochloride", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Rifabutin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ethambutol", 
                "Rifabutin"
            ]
        }, 
        "keyword": [
            "Rifabutin", 
            "Mycobacterium avium-intracellulare Infection", 
            "Drug Therapy, Combination", 
            "Ethambutol", 
            "Acquired Immunodeficiency Syndrome"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Sacramento", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "95817"
                }, 
                "name": "Univ of California - Davis Med Ctr / CARES"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "An Open-Label Randomized Pharmacokinetic/Pharmacodynamic Study of Mycobutin (Rifabutin) or Rifabutin in Combination With Myambutol (Ethambutol) for Prophylaxis of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts <= 100 Cells/mm3", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 4", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002343"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pharmacia", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 1997"
    }, 
    "geocoordinates": {
        "Univ of California - Davis Med Ctr / CARES": "38.582 -121.494"
    }
}